newsfilter
← Latest News
GlobeNewswire·

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1, double-blind,